There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sangamo Biosciences (SGMO) and Dynavax (DVAX) with bullish sentiments.
Sangamo Biosciences (SGMO)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Sangamo Biosciences. The company’s shares closed yesterday at $12.17.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 22.4% and a 47.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sangamo Biosciences with a $15 average price target.
See today’s analyst top recommended stocks >>
Dynavax (DVAX)
Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Dynavax today and set a price target of $20. The company’s shares closed yesterday at $2.99, close to its 52-week low of $2.60.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.9% and a 46.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dynavax with a $16.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
